The $90m will be used to launch the second of two pivotal trials examining the company’s therapy for patients living with heart failure.

Topline data from Hengrui’s Phase II trial for its GLP-1/GIP product demonstrated a statistically significant mean weight loss of 22.8%.

Amgen presented data about its obesity drug at JP Morgan 2025, stating it hopes the once-monthly dosing will make it an attractive therapy.

Verismo Therapeutics has commenced the first patient dosing in its multicentre Phase I CELESTIAL-301 trial of SynKIR-310.

Analytics company GlobalData has shared its optimism regarding the future of Novartis’ spinal muscular atrophy (SMA) gene transfer therapy – onasemnogene abeparvovec (OAV101 IT) – which could become ...

There is a significant discourse in the literature when estimating clinical trial costs due to the lack of transparency throughout the industry regarding the true expense of bringing a drug from bench ...

There are over 300 glucagon-like peptide-1 receptor (GLP-1R) drugs in an active stage of development as the astounding success of Novo Nordisk’s GLP-1R obesity drug, Wegovy, has ignited a surge in ...

HMNC has completed the subject randomisation in its Phase IIb OLIVE trial of BH-200 for major depressive disorder (MDD) treatment.

Pfizer's Phase III trial of sasanlimab with BCG in subjects with BCG-naïve, high-risk NMIBC, has met its primary endpoint.

The Phase Ia trial is designed to assess the company’s drug designed to target chemicals thought to be a cause of Alzheimer’s disease.

The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...